BioMerieux SA
BIM
Company Profile
Business description
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
Contact
Marcy l’Etoile
Lyon69280
FRAT: +33 478872000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
15,226
Stocks News & Analysis
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
stocks
Cheap retail REIT with an attractive yield
Lower consumer spending unlikely to buckle this retail REIT.
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,182.20 | 66.50 | 0.73% |
| CAC 40 | 8,447.27 | 63.26 | 0.75% |
| DAX 40 | 24,910.41 | 16.40 | 0.07% |
| Dow JONES (US) | 51,999.67 | 328.64 | 0.64% |
| FTSE 100 | 10,494.21 | 63.59 | 0.61% |
| HKSE | 24,270.87 | 223.08 | -0.91% |
| NASDAQ | 26,376.34 | 307.60 | -1.15% |
| Nikkei 225 | 69,926.08 | 521.58 | 0.75% |
| NZX 50 Index | 13,408.32 | 17.81 | -0.13% |
| S&P 500 | 7,511.35 | 42.94 | -0.57% |
| S&P/ASX 200 | 8,965.40 | 64.60 | 0.73% |
| SSE Composite Index | 4,088.74 | 3.15 | -0.08% |